Lemaître to join Link Technologies Ltd. as non-executive Director
BELLSHILL, SCOTLAND, 25 February 2015: LINK (www.linktech.co.uk), the innovative developer and manufacturer of nucleic acid reagents, has announced the appointment of Dr Marc Lemaître to its company board as a non-executive Director. Dr Lemaître brings to LINK his extensive experience in the nucleic acids field, supporting LINK’s strategic direction in developing both its established nucleic acid reagents business and its growing range of innovative reagents for oligo therapeutics and diagnostics.
Since obtaining a PhD in Biochemistry from the University of Liège, Dr Lemaître has been working in the field of nucleic acids for over 25 years, holding senior positions within various high profile CMOs, Pharma and Biotech companies. Notably, he oversaw the implementation of IVD oligo production at Eurogentec, SA during 13 years with the company. Based in the USA since 2006, Marc worked for Glen Research before being appointed in 2009 as CEO of Girindus America, a CMO with a focus on the cGMP manufacture of oligonucleotides for therapeutic applications. Whilst there he also acted as President of Girindus AG. Since negotiating the merger between Nitto-Denko Avecia and the US operations of Girindus in 2013, Marc has been working as an independent consultant.
Commenting on his appointment, Dr Lemaître said: “I was deeply honoured to be offered the opportunity to join LINK’s board. I’ve known LINK for quite some time as a customer and so already appreciate how much effort the team focuses on customer satisfaction and product quality. It’s therefore a great pleasure to now be involved with the strategic definition of LINK’s future business, and I look forward to helping secure and develop the company’s leading position in the nucleic acid chemistry landscape.”
Dr David Ricketts, CEO of LINK, added: “We are delighted to have Marc on board. His vast experience in our industry, particularly in the largest market of oligonucleotide reagents, will be invaluable as we continue to build our company’s presence in the nucleic acids arena. Together with the recent incorporation of our Scientific Advisory Board, this appointment underlines our ambition and focus to meet customers’ needs on a global scale.”
Editors’ Notes
About Marc Lemaître
Marc Lemaître holds a degree in Organic Chemistry and a PhD in Biochemistry from the University of Liège, Belgium. Since 1980, Marc’s professional interests have focused on the study of nucleic acids. Marc has held positions of increasing seniority in R&D, operations, business development, and general management within various high profile CMOs, Pharma and Biotech companies, in particular spending 13 years at Eurogentec, SA which included the implementation of IVD oligo production. Based in the USA since 2006, he has worked for Glen Research, before being recruited in 2009 as CEO of Girindus America, a CMO with a focus on the cGMP manufacture of oligonucleotides for therapeutic applications. In this role, Marc also held the legal responsibility of President of the management board of the German listed company Girindus AG, adding invaluable experience of leadership of a public company. After negotiating the merger between Nitto-Denko Avecia and the US operations of Girindus, Marc is now working as an independent consultant. He is also director and treasurer of the Oligonucleotide Therapeutics Society (2015-2016 term).
About LINK
LINK, an ISO9001:2008 certified manufacturer, is a leading kilo-scale supplier of speciality reagents for oligonucleotide synthesis and modification. The company’s main markets are university and commercial research departments, oligonucleotide synthesis companies, plus, increasingly, larger Contract Manufacturing Organisations (CMOs) in the biotech sector.
LINK has also forged successful links to academia working closely with many UK universities. In tandem with internal research and development, the Company has an excellent record in bringing in-licence products to market with various worldwide commercial partners. LINK is a trading name of Link Technologies Ltd, Scotland.
For further information see: www.linktech.co.uk.
Help employers find you! Check out all the jobs and post your resume.
BELLSHILL, SCOTLAND, 25 February 2015: LINK (www.linktech.co.uk), the innovative developer and manufacturer of nucleic acid reagents, has announced the appointment of Dr Marc Lemaître to its company board as a non-executive Director. Dr Lemaître brings to LINK his extensive experience in the nucleic acids field, supporting LINK’s strategic direction in developing both its established nucleic acid reagents business and its growing range of innovative reagents for oligo therapeutics and diagnostics.
Since obtaining a PhD in Biochemistry from the University of Liège, Dr Lemaître has been working in the field of nucleic acids for over 25 years, holding senior positions within various high profile CMOs, Pharma and Biotech companies. Notably, he oversaw the implementation of IVD oligo production at Eurogentec, SA during 13 years with the company. Based in the USA since 2006, Marc worked for Glen Research before being appointed in 2009 as CEO of Girindus America, a CMO with a focus on the cGMP manufacture of oligonucleotides for therapeutic applications. Whilst there he also acted as President of Girindus AG. Since negotiating the merger between Nitto-Denko Avecia and the US operations of Girindus in 2013, Marc has been working as an independent consultant.
Commenting on his appointment, Dr Lemaître said: “I was deeply honoured to be offered the opportunity to join LINK’s board. I’ve known LINK for quite some time as a customer and so already appreciate how much effort the team focuses on customer satisfaction and product quality. It’s therefore a great pleasure to now be involved with the strategic definition of LINK’s future business, and I look forward to helping secure and develop the company’s leading position in the nucleic acid chemistry landscape.”
Dr David Ricketts, CEO of LINK, added: “We are delighted to have Marc on board. His vast experience in our industry, particularly in the largest market of oligonucleotide reagents, will be invaluable as we continue to build our company’s presence in the nucleic acids arena. Together with the recent incorporation of our Scientific Advisory Board, this appointment underlines our ambition and focus to meet customers’ needs on a global scale.”
Editors’ Notes
About Marc Lemaître
Marc Lemaître holds a degree in Organic Chemistry and a PhD in Biochemistry from the University of Liège, Belgium. Since 1980, Marc’s professional interests have focused on the study of nucleic acids. Marc has held positions of increasing seniority in R&D, operations, business development, and general management within various high profile CMOs, Pharma and Biotech companies, in particular spending 13 years at Eurogentec, SA which included the implementation of IVD oligo production. Based in the USA since 2006, he has worked for Glen Research, before being recruited in 2009 as CEO of Girindus America, a CMO with a focus on the cGMP manufacture of oligonucleotides for therapeutic applications. In this role, Marc also held the legal responsibility of President of the management board of the German listed company Girindus AG, adding invaluable experience of leadership of a public company. After negotiating the merger between Nitto-Denko Avecia and the US operations of Girindus, Marc is now working as an independent consultant. He is also director and treasurer of the Oligonucleotide Therapeutics Society (2015-2016 term).
About LINK
LINK, an ISO9001:2008 certified manufacturer, is a leading kilo-scale supplier of speciality reagents for oligonucleotide synthesis and modification. The company’s main markets are university and commercial research departments, oligonucleotide synthesis companies, plus, increasingly, larger Contract Manufacturing Organisations (CMOs) in the biotech sector.
LINK has also forged successful links to academia working closely with many UK universities. In tandem with internal research and development, the Company has an excellent record in bringing in-licence products to market with various worldwide commercial partners. LINK is a trading name of Link Technologies Ltd, Scotland.
For further information see: www.linktech.co.uk.
Help employers find you! Check out all the jobs and post your resume.
